ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2017
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Efficacy and Safety of Manual Therapy for Symptoms Associated with Multiple Sclerosis: A Systematic Review and Meta-Analysis.Journal of integrative and complementary medicine · 2022Pooled it
- A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update.Archives of physical medicine and rehabilitation · 2021Pooled it
- Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.PharmacoEconomics · 2018Pooled it
- Neurologic Medication Costs in a Direct-to-Consumer Pharmacy vs Commercial Insurance Plans.JAMA network open · 2025Article
- Generics, Biosimilars and Follow-On Non-Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists.European journal of neurology · 2025Review
- Financial burden of out of pocket nonpharmacological therapies in an Austrian multiple sclerosis cohort.Scientific reports · 2025Article
- Multiple sclerosis subgroups: Data-driven clusters based on patient-reported outcomes and a large clinical sample.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Impact of Fingolimod Discontinuation Strategy on Recurrence of Disease Activity in Individuals With Multiple Sclerosis.International journal of MS care · 2024Article
- Portable multi-focal visual evoked potential diagnostics for multiple sclerosis/optic neuritis patients.Documenta ophthalmologica. Advances in ophthalmology · 2024Article
- Healthcare resource utilization and economic burden of multiple sclerosis in Chinese patients: results from a real-world survey.Scientific reports · 2024Article
- Tolerability and Acceptance of Switching from Brand to Generic Glatiramer Acetate in Multiple Sclerosis.Journal of clinical medicine · 2024Article
- Neuroprotective effect of curcumin against experimental autoimmune encephalomyelitis-induced cognitive and physical impairments in mice: an insight into the role of the AMPK/SIRT1 pathway.Inflammopharmacology · 2024Article
- Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy.Drug design, development and therapy · 2024Review
- Costs of Potential Medication Wastage Due to Switching Treatment Among People With Multiple Sclerosis.Journal of health economics and outcomes research · 2024Article
- Patterns of multiple sclerosis presentation to the emergency department.Frontiers in neurology · 2024Article
- Portable Multi-focal Visual Evoked Potential Diagnostics for Multiple Sclerosis/Optic Neuritis patients.medRxiv : the preprint server for health sciences · 2023Article
- Article
- Principles for Just Prioritization of Expensive Biological Therapies in the Danish Healthcare System.Journal of bioethical inquiry · 2023Article
- Decentralised clinical trials in multiple sclerosis research.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020.Neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a disabling, chronic disease that imposes a significant economic burden on patients and the US healthcare system. The largest cost component for individuals with MS are prescription drugs, specifically disease-modifying therapies (DMTs). Despite an increase in the number and diversity of DMTs over the past 10 years, acquisition costs for all DMTs have escalated dramatically at rates substantially higher than medical inflation. Currently, costs for most DMTs exceed $70,000 a year. Recent cost-effectiveness studies suggest the cost for nearly all DMTs exceeds generally accepted thresholds for what is considered a good value in the USA, even after factoring expected rebates. The high cost of DMTs is symptomatic of systemic dysfunction in the pharmaceutical market. Strategies aimed at reigning in high-cost medications include proposals ranging from increasing pricing transparency to allowing Medicare to negotiate directly with manufacturers. Because the economics of pharmaceuticals are inherently complex, a diversity of approaches will be required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.